Press "Enter" to skip to content

Setmelanotide Success for More Genetic Obesities; No Breast Cancer-Metformin Link

Recently approved setmelanotide (Imcivree) showed promise as a treatment for severe obesity arising from genetic variants in the MC4R pathway, Rhythm Pharmaceuticals announced.

Overweight or obesity could be detrimental to brain health, potentially magnifying Alzheimer’s disease. (The Journal of Alzheimer’s Disease)

A large study found no link between metformin and the development of breast cancer in women with type 2 diabetes. “[T]hese findings suggest that having type 2 diabetes may increase the risk of developing breast cancer, but that taking metformin may protect against developing ER [estrogen receptor]-positive breast cancer, the most common type of breast cancer,” said study author Dale Sandler, PhD, of the National Institutes of Health, in a statement. (Annals of Oncology)

Is hypertension being dismissed as part of menopausal symptoms in older women? (U.S. News & World Report)

The adverse health effects of obesity likely can’t be offset by an active lifestyle alone. (Labroots)

People with obesity who stuck to a 16:8 time-restricted diet for 12 weeks lost an average 7.3 pounds. (PLOS One)

The Endocrine Society, along with other organizations, are intervening in an appeal in the U.K.’s High Court following the decision that minors under the age of 16 can’t give informed consent for pubertal suppression.

Social conditions reinforced by systemic racism are likely an underlying cause of health disparities for people with diabetes, according to an article in the Journal of Clinical Endocrinology & Metabolism.

  • Kristen Monaco is a staff writer, focusing on endocrinology, psychiatry, and dermatology news. Based out of the New York City office, she’s worked at the company for nearly five years.